Tae-Hwan Kim1, Shin-Seok Lee2, Won Park3, Yeong Wook Song4, Chang-Hee Suh5, SooKyoung Kim6, Young Nam Lee6, Dae Hyun Yoo7. 1. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. 2. Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea. 3. School of Medicine, Inha University, Incheon, Republic of Korea. 4. Rheumatology, Seoul National University Hospital, Seoul National University, Seoul, Republic of Korea. 5. Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea. 6. Celltrion Healthcare Co. Ltd., Incheon, Republic of Korea. 7. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. dhyoo@hanyang.ac.kr.
Abstract
BACKGROUND: The infliximab biosimilar CT-P13 has widely received regulatory approval in all indications of reference infliximab, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). OBJECTIVE: This retrospective analysis investigated drug survival and long-term safety and effectiveness of CT-P13 in patients with RA or AS in the Republic of Korea. METHODS: This non-interventional, retrospective, multicenter analysis collected medical record data for adult patients with RA or AS who received CT-P13 treatment at five Korean referral hospitals (2012-2017). Drug survival and long-term safety were primary outcomes. The secondary outcome was long-term effectiveness, assessed by disease activity measures. RESULTS: Overall, 491 patients were treated with CT-P13 (154 patients with RA [135 infliximab-naïve; 19 switched from reference infliximab]; 337 patients with AS [219 infliximab-naïve; 118 switched from reference infliximab]). Drug survival was similar in naïve and switched patients. Treatment-emergent adverse events (TEAEs) occurred in 31.8% and 29.4% of patients with RA and AS, respectively; incidence was similar in naïve and switched groups. Upper respiratory tract infection, influenza-like illness, and urticaria were the most common TEAEs. Overall, nine (1.8%) patients experienced serious adverse events (SAEs) deemed potentially drug-related; SAEs led to permanent CT-P13 discontinuation in five (1.0%) patients, including three with tuberculosis. Disease activity decreased over time. CONCLUSION: Up to 5 years of CT-P13 treatment was safe and effective in patients with RA and AS, based on drug survival, incidence of TEAEs, and disease activity. Drug survival and safety were similar in naïve patients and switched groups, supporting switching from reference infliximab to CT-P13.
BACKGROUND: The infliximab biosimilar CT-P13 has widely received regulatory approval in all indications of reference infliximab, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). OBJECTIVE: This retrospective analysis investigated drug survival and long-term safety and effectiveness of CT-P13 in patients with RA or AS in the Republic of Korea. METHODS: This non-interventional, retrospective, multicenter analysis collected medical record data for adult patients with RA or AS who received CT-P13 treatment at five Korean referral hospitals (2012-2017). Drug survival and long-term safety were primary outcomes. The secondary outcome was long-term effectiveness, assessed by disease activity measures. RESULTS: Overall, 491 patients were treated with CT-P13 (154 patients with RA [135 infliximab-naïve; 19 switched from reference infliximab]; 337 patients with AS [219 infliximab-naïve; 118 switched from reference infliximab]). Drug survival was similar in naïve and switched patients. Treatment-emergent adverse events (TEAEs) occurred in 31.8% and 29.4% of patients with RA and AS, respectively; incidence was similar in naïve and switched groups. Upper respiratory tract infection, influenza-like illness, and urticaria were the most common TEAEs. Overall, nine (1.8%) patients experienced serious adverse events (SAEs) deemed potentially drug-related; SAEs led to permanent CT-P13 discontinuation in five (1.0%) patients, including three with tuberculosis. Disease activity decreased over time. CONCLUSION: Up to 5 years of CT-P13 treatment was safe and effective in patients with RA and AS, based on drug survival, incidence of TEAEs, and disease activity. Drug survival and safety were similar in naïve patients and switched groups, supporting switching from reference infliximab to CT-P13.
Authors: Lars Erik Kristensen; Rieke Alten; Luis Puig; Sandra Philipp; Tore K Kvien; Maria Antonia Mangues; Frank van den Hoogen; Karel Pavelka; Arnold G Vulto Journal: BioDrugs Date: 2018-10 Impact factor: 5.807
Authors: Petra Baji; Márta Péntek; Sándor Szántó; Pál Géher; László Gulácsi; Orsolya Balogh; Valentin Brodszky Journal: Eur J Health Econ Date: 2014-05-16
Authors: Dae Hyun Yoo; Artur Racewicz; Jan Brzezicki; Roman Yatsyshyn; Edgardo Tobias Arteaga; Asta Baranauskaite; Carlos Abud-Mendoza; Sandra Navarra; Vladimir Kadinov; Irmgadt Goecke Sariego; Seung Suh Hong; Sung Young Lee; Won Park Journal: Arthritis Res Ther Date: 2016-04-02 Impact factor: 5.156
Authors: Won Park; Dae Hyun Yoo; Janusz Jaworski; Jan Brzezicki; Andriy Gnylorybov; Vladimir Kadinov; Irmgadt Goecke Sariego; Carlos Abud-Mendoza; William Jose Otero Escalante; Seong Wook Kang; Daina Andersone; Francisco Blanco; Seung Suh Hong; Sun Hee Lee; Jürgen Braun Journal: Arthritis Res Ther Date: 2016-01-20 Impact factor: 5.156
Authors: Dae Hyun Yoo; Nenad Prodanovic; Janusz Jaworski; Pedro Miranda; Edgar Ramiterre; Allan Lanzon; Asta Baranauskaite; Piotr Wiland; Carlos Abud-Mendoza; Boycho Oparanov; Svitlana Smiyan; HoUng Kim; Sang Joon Lee; SuYeon Kim; Won Park Journal: Ann Rheum Dis Date: 2016-04-29 Impact factor: 19.103
Authors: Won Park; Dae Hyun Yoo; Pedro Miranda; Marek Brzosko; Piotr Wiland; Sergio Gutierrez-Ureña; Helena Mikazane; Yeon-Ah Lee; Svitlana Smiyan; Mie-Jin Lim; Vladimir Kadinov; Carlos Abud-Mendoza; HoUng Kim; Sang Joon Lee; YunJu Bae; SuYeon Kim; Jürgen Braun Journal: Ann Rheum Dis Date: 2016-04-26 Impact factor: 19.103
Authors: Pekka Kurki; Hye-Na Kang; Niklas Ekman; Ivana Knezevic; Martina Weise; Elena Wolff-Holz Journal: BioDrugs Date: 2022-05-21 Impact factor: 7.744